On September 30, PHARMARON rose 3.33% in regular trading, trading at HK$30.88/share, with turnover of HK$26.23 million. The gain came as multiple positive catalysts converged on the CXO sector.

On the policy front, the recently released 15th Five-Year Plan for Pharmaceutical Industry Development formally designated biopharmaceuticals as a national emerging pillar industry, setting an annual growth target of no less than 20% for the innovative drug sector. AI-driven drug discovery was highlighted as a key development priority, while CDMO/CRO segments received explicit policy endorsement, fueling a broad-based CXO sector rally. Industry analysts noted that CXO remains one of the brightest sub-sectors in healthcare, with CDMO leaders and CRO segments operating at elevated levels of activity.

Fundamentally, the company reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with adjusted net profit of RMB 909 million, up 20.3%. Full-year revenue guidance calls for 15%-20% growth. Morgan Stanley recently assigned an Overweight rating with a target price of HK$35.6, while also raising its stake to 7.15% of H shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)